Floatz logo

Epirubicin

Adenoid Cystic Carcinoma

Seagen, a wholly owned subsidiary of PfizerPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Adenoid Cystic Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
VIPIVOTIDE TETRAXETAN
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2CCC
Cyclophosphamide
Seagen, a wholly owned subsidiary of Pfizer
Phase 1/2CCC
Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →